Related Experiment Video
Updated: Aug 19, 2026

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Repetitive profound thrombocytopenia after treatment with tirofiban: a case report
Beyhan Eryonucu1, Mustafa Tuncer, Reha Erkoc
1Cardiology Department, Medical Faculty, Yüzüncü Yil University, Van, Turkey. drbeyhan@yahoo.com
The GPIIb/IIIa inhibitors are used in the acute coronary syndromes and interventional cardiology as antiplatelet agents. These drugs induce thrombocytopenia in approximately 1-5% of patients. Thrombocytopenia is rapid in onset and antibody mediated. Abciximab is associated with higher incidence of thrombocytopenia than eptifibatide and tirofiban. Profound thrombocytopenia has reportedly been an issue with abciximab, but not with tirofiban. We reported a case of acute profound thrombocytopenia due to on tirofiban treatment in the same patient at two different times.
The GPIIb/IIIa inhibitors are used in the acute coronary syndromes and interventional cardiology as antiplatelet agents. These drugs induce thrombocytopenia in approximately 1-5% of patients. Thrombocytopenia is rapid in onset and antibody mediated. Abciximab is associated with higher incidence of thrombocytopenia than eptifibatide and tirofiban. Profound thrombocytopenia has reportedly been an issue with abciximab, but not with tirofiban. We reported a case of acute profound thrombocytopenia due to on tirofiban treatment in the same patient at two different times.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Clot Retraction and Fibrinolysis
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins

